Q3 2021 Investor Relations Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Oncology grew 5% in Q3 driven by strong execution
Oncology net sales
USD bn, % cc
+5%
3.9
3.7
0.1
0.1
Launches1
Growth drivers²
Base business, Gx³
10.9
0.3'
+4%
11.6
0.4
+17%
1.6
1.9
+16%
4.5
5.4
2.0
1.9
6.0
5.8
-5%
-6%
Q3 2020
Q3 2021
9M 2020
9M 2021
■ Growth drivers and recent
launches contribute 52% of
sales (vs. 47% in Q3 2020)
Strong double-digit growth
for JakaviⓇ, PromactaⓇ/
RevoladeⓇ and KisqaliⓇ
■ COVID-19 situation
normalizing with patient
visits, diagnosis and
treatment rates increasing,
but still below pre-COVID
1. Launches include Piqray®, Adakveo® and TabrectaⓇ
2. Growth drivers include PromactaⓇ/Revolade®, TafinlarⓇ+ MekinistⓇ, KisqaliⓇ, LutatheraⓇ, KymriahⓇ and JakaviⓇ (marketed by Novartis ex-US). 3. Base business - other brands. Gx
include AfinitorⓇ, ExjadeⓇ / JadenuⓇ, GlivecⓇ and SandostatinⓇ All % growth relate to cc unless otherwise stated.
33 Investor Relations | Q3 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation